Patent · US Active

Modified iRNA agents

US11312957B2 · kind B2 · utility

0Cited by

24References

20Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Muthiah Manoharan · Carlsbad, US
Venkitasamy Kesavan · Woburn, US
Kallanthottathil G. Rajeev · Wayland, US

Key dates

Filing date	Jul 26, 2019
Grant date	Apr 26, 2022
Priority date	—
Expiry date	Dec 1, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2330/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.